Combination therapy for treating breast cancer using antiestrogen, ERA-923, and the mammalian target of rapamycin inhibitor, temsirolimusTyler Sadler, Yixian Zhang(Fujian Medical University)Endocrine Related CancerSeptember 1, 200610.1677/erc.1.01170Cited by 38SaveCiteExport RISWatch citationsRelated PapersDown-modulation of cancer targets using locked nucleic acid (LNA)-based antisense oligonucleotides without transfection|Gene Therapy|2010|67